Literature DB >> 2303708

Role of carbohydrate moiety of IL-5. Effect of tunicamycin on the glycosylation of IL-5 and the biologic activity of deglycosylated IL-5.

A Tominaga1, T Takahashi, Y Kikuchi, S Mita, S Naomi, N Harada, N Yamaguchi, K Takatsu.   

Abstract

IL-5 is a T cell-derived lymphokine that induces B cell growth and differentiation in murine systems. In this study, we examined the role of carbohydrate moiety of IL-5 in the expression of biological function. IL-5 polypeptides translated in Xenopus oocytes were heterogeneous in terms of isoelectric point (pI 4.7 to 8.0) and m.w. (45,000 to 60,000 under nonreducing conditions) and yielded m.w. of 25,000 to 30,000 under reducing conditions. Treatment of rIL-5 with N-glycanase under reducing conditions yielded an IL-5 monomer of m.w. 12,000 to 14,000. Furthermore, deglycosylated rIL-5 that had been translated in the presence of tunicamycin showed very limited heterogeneity by two-dimensional gel electrophoresis (first dimension, nonequilibrium pH gradient electrophoresis; second dimension, SDS-PAGE). The m.w. was 27,000 to 28,000 under non-reducing conditions and migrated to m.w. 13,000 to 14,000 under reducing conditions. These results indicate that IL-5 is a glycoprotein carrying the N-glycosidically-linked carbohydrates. Treatment of IL-5 with sialidase caused the decrease in the heterogeneity in isoelectric point of IL-5. Deglycosylated rIL-5 that had been obtained from tunicamycin-treated oocytes could bind to IL-5-responding cells (T88-M), which express both high- and low-affinity IL-5 receptors, as efficient as intact rIL-5 under high-affinity conditions. Scatchard plot analysis of equilibrium binding of 35S-labeled rIL-5 to T88-M cells revealed that the dissociation constants (Kd) of glycosylated rIL-5 and deglycosylated rIL-5 were 127 pM and 110 pM, respectively. IL-5 activities determined by both B cell growth and differentiation assays were not affected by deglycosylation. These results indicate that N-linked glycoside moiety of IL-5 molecules may not play an essential role in the expression of its activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303708

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Cytokines in posterior uveitis: an update.

Authors:  V K Singh; G Rai
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Human interleukin-5 expressed in Escherichia coli has N-terminal modifications.

Authors:  K Rose; P O Regamey; R Anderegg; T N Wells; A E Proudfoot
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

3.  Molecular cloning and expression of the murine interleukin-5 receptor.

Authors:  S Takaki; A Tominaga; Y Hitoshi; S Mita; E Sonoda; N Yamaguchi; K Takatsu
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

4.  Structure-function analysis of interleukin-5 utilizing mouse/human chimeric molecules.

Authors:  A N McKenzie; S C Barry; M Strath; C J Sanderson
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

Review 5.  Interleukin-5 and IL-5 receptor in health and diseases.

Authors:  Kiyoshi Takatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

6.  Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists.

Authors:  S C Bischoff; T Brunner; A L De Weck; C A Dahinden
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

Review 7.  Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease.

Authors:  S Greenfeder; S P Umland; F M Cuss; R W Chapman; R W Egan
Journal:  Respir Res       Date:  2001-03-08

8.  Identification of the second subunit of the murine interleukin-5 receptor: interleukin-3 receptor-like protein, AIC2B is a component of the high affinity interleukin-5 receptor.

Authors:  S Takaki; S Mita; T Kitamura; S Yonehara; N Yamaguchi; A Tominaga; A Miyajima; K Takatsu
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

9.  Molecular cloning and expression of the human interleukin 5 receptor.

Authors:  Y Murata; S Takaki; M Migita; Y Kikuchi; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production.

Authors:  A Tominaga; S Takaki; N Koyama; S Katoh; R Matsumoto; M Migita; Y Hitoshi; Y Hosoya; S Yamauchi; Y Kanai
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.